AbbVie Inc. (ABBV) Stock: Phase 3 Lymphoma Trial Cuts Progression Risk 51%

TLDR AbbVie Phase 3 lymphoma trial cuts progression or death risk by 51% in DLBCL Epcoritamab plus R-CHOP delivers a major Phase 3 win in frontline lymphoma care AbbVie gains fresh lymphoma data as EPCORE DLBCL-2 meets its primary endpoint Phase 3 results strengthen AbbVie’s bispecific strategy in frontline DLBCL care AbbVie and Genmab plan [...]

The post AbbVie Inc. (ABBV) Stock: Phase 3 Lymphoma Trial Cuts Progression Risk 51% appeared first on Blockonomi.